Clinical trial · Interventional
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT: PANDORE-PANC-IPC 2021-082
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study consists of a 25 ml blood sample collection: * Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression Collection of tumor material: * During the initial diagnostic biopsy * On the operating room in case of surgery * At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Non-resectable | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| collection of blood and tumor samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- collection of blood and tumor samples
- interventionNames
- Other: collection of blood and tumor samples
Primary outcomes (1)
- measure
- Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma
- timeFrame
- up to 6 years
- description
- Analysis of the impact of identified biomarkers on overall patient survival and tumour response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification) * No previous treatment with surgery or chemotherapy * Age \> 18 years * General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery) * Therapeutic management at the Paoli-Calmettes Institute * Signature of the informed consent specific to the PANDORE-PANC study * Patient affiliated to a social security system or benefiting from such a system Exclusion Criteria: * Metastatic disease * Pancreatic tumor of a histological type other than adenocarcinoma * Other tumor under treatment or for which treatments have been completed for \< 1 year * Pregnant or breastfeeding women * Person in an emergency situation * Person of legal age under legal protection (guardianship, curatorship or safeguard of justice) or unable to give consent.
References
Publications (0)
Data not yet available